PSNL · Personalis

The thesis

Personalis trades as a claim on Tempus AI's agreed takeover at a fixed $16.25 per share. With the shares already close to that value and no rival bid on record, they are more likely to lag the S&P 500 than to lead it. The Personalis stockholder vote on 30 November 2026 and the closing that follows settle the case.

The shares closed at $15.96 on 11 November 2026, below the $16.25 deal value. Tempus's Form S-4/A Amendment No. 2, filed 20 October 2026, sets a virtual special meeting for 30 November 2026 at 9:00 a.m. Pacific Time, with a record date of 15 October 2026. Personalis's third-quarter release on 4 November 2026 gave no expected closing date. Company news since then contains no deal update.

The rating is Low because the deal caps the upside. Unless the offer improves, the return left is the gap between the share price and $16.25 plus whatever time it takes to close. A strong market over the next three months would beat that.

Bullish and bearish views on Personalis, Inc.

The bull case on Personalis, Inc. (PSNL), in brief: the main regulatory hurdle is cleared. The bear case: No richer offer is in view.

Bull case

• The main regulatory hurdle is cleared. The Hart-Scott-Rodino Act waiting period expired at 11:59 p.m. Eastern on 2 October 2026, according to the Personalis 8-K accepted 6 October 2026. Only Personalis stockholders need to vote; Tempus holders do not.
• The vote has a fixed date and board backing. The proxy sets the meeting for 30 November 2026, and the Personalis board unanimously recommends voting for the merger. Tempus's 2 November 2026 results release also names that meeting date.
• The Tempus price gives room above the collar. Under the merger terms, value per share falls below $16.25 only if Tempus's 15-day average price is at or below $48.42. The New Moon Special Situations newsletter cited a Tempus close of $67.76 on 21 October 2026.
• Both businesses are growing. Tempus reported third-quarter 2026 revenue of $411.5 million, up 23% year over year, on 2 November 2026. Personalis reported third-quarter revenue of $25.6 million against $14.5 million a year earlier, and clinical test volume of 13,157 against 4,388, on 4 November 2026.

Bear case

• No richer offer is in view. BTIG downgraded the shares to Neutral on 6 October 2026, saying it sees no higher offer. Tempus chief executive Eric Lefkofsky said on 15 September 2026 that he did not expect a competing bid (Form 425).
• The contract blocks a superior offer. The S-4 filed 31 August 2026 states Personalis cannot end the agreement to accept a superior proposal. Termination fees of about $76.8 million apply in both directions. The S-4 also shows the rival bidder, called Party A, offered only $17.00 per share verbally, in stock, before signing.
• Insiders sold near the deal value. Chief executive Christopher Hall sold 29,112 shares in the open market at $15.87 on 3 November 2026, per an SEC Form 4 filed 4 November 2026. Four officers, including Hall, sold at $16.22 on 18 September 2026, per Form 4s filed 22 September 2026.
• Standalone losses widened. Personalis reported a third-quarter net loss of $33.8 million, or $0.32 per share, on 4 November 2026, against $21.7 million, or $0.24, a year earlier. Analysts had expected a loss of $0.25 per share, per Benzinga. Guidance was withdrawn on 4 August 2026.

Price setup

The shares closed at $15.96 on 11 November 2026, after closes between $15.55 and $15.96 from 4 November to 11 November 2026. That range sits just under the $16.25 deal value. The 50-day moving average is $16.12 and the 200-day is $11.52, both as of 11 November 2026. The shares rose 10.7% over three months.

The 52-week high is $18.89, reached intraday on 21 August 2026, and the last close is 15.5% below it. The 52-week closing low is $5.04 on 29 April 2026, before the takeover was announced on 20 July 2026. Since the announcement the price has tracked the deal value and the deal timetable, not the Personalis business.

Value is fixed at $16.25 only while Tempus's 15-day volume-weighted average price stays above $48.42. At or below it, holders get 0.3356 Tempus shares per Personalis share, and value falls with Tempus. A widening discount to $16.25 would mean the market is doubting completion or pricing a weaker Tempus.

Catalysts ahead

• 30 November 2026: Personalis special stockholder meeting on the Tempus merger, 9:00 a.m. Pacific Time. A yes vote clears the last stockholder condition for closing; a no vote or a postponement would put standalone value back in play.
• ~31 December 2026 (est.): Merger closing and the Tempus 15-day volume-weighted average price that sets the final exchange ratio. No filing states a closing date; the averaging period fixes the Tempus stock holders receive and tests whether Tempus stays above $48.42.

What would change the view

A daily close above $18.67, near the 52-week high and well above the $16.25 deal value, which would show the shares leading the S&P 500; a raised Tempus offer or a rival bid above $16.25 would also prove the call wrong.

What it trades with

Above the $48.42 Tempus level, Personalis shares follow the odds and timing of completion, not the broad market or the diagnostics group. If Tempus falls toward $48.42, the shares start to move with Tempus. Below $46.00 on the final measured price, Personalis gains a right to walk away, which would tie the shares back to the standalone business and its cash of about $190.6 million at 30 September 2026.